-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

527 Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell DiseaseClinically Relevant Abstract

Gene Therapy and Transfer
Program: Oral and Poster Abstracts
Type: Oral
Session: 801. Gene Therapy and Transfer: Immune Disorders, CAR-T Cells, and B-hemoglobinopathies
Sunday, December 10, 2017: 5:29 PM
Bldg C, Lvl 1, C101 Aud (Georgia World Congress Center)

Julie Kanter, MD1, Mark C. Walters, MD2, Matthew Hsieh, MD3, Lakshmanan Krishnamurti, MD4, Janet L. Kwiatkowski, MD5, Rammurti Kamble, MD6, Christof von Kalle, MD7*, Marcelyne Joseney-Antoine8*, Francis J. Pierciey Jr.8*, Weiliang Shi, PhD8*, Mohammed Asmal, MD, PhD8*, Alexis A Thompson, MD, MPH9 and John F Tisdale, MD3

1Lifespan Comprehensive Sickle Cell Center, Medical University Of South Carolina, Charleston, SC
2UCSF Benioff Children’s Hospital, Oakland, CA
3MCHB, NHLBI/NIDDK, National Institutes of Health, Bethesda, MD
4Department of Pediatrics, Division of Hematology/Oncology/BMT, Emory University School of Medicine, Atlanta, GA
5Children's Hospital of Philadelphia, Philadelphia, PA
6Baylor College of Medicine Methodist Hospital, Houston, TX
7German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Heidelberg, Germany
8bluebird bio, Inc., Cambridge, MA
9Division of Hematology, Oncology & Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL


β-globin gene transfer into hematopoietic stem cells (HSCs) may reduce or eliminate the acute symptoms and long-term complications of sickle cell disease (SCD). LentiGlobin Drug Product (DP) contains autologous CD34+ cells transduced with the betibeglogene darolentivec (BB305) lentiviral vector, which encodes a β-globin with a single point mutation (AT87Q) designed to confer anti-sickling properties similar to γ-globin. HGB-206 is a multi-center, phase 1/2 safety and efficacy study of LentiGlobin DP in adults with severe SCD. In 2016, the HGB-206 protocol was modified to increase DP vector copy number (VCN), require pre-harvest transfusions, increase target busulfan levels, and explore the use of plerixafor for mobilization and apheresis for cell collection. We present new data from the initial 7 patients (group A) and initial data from 2 newly treated patients (group B, with increased DP VCN and pre-harvest transfusions). Results from exploratory plerixafor-mediated HSC mobilization will be reported separately.


Patients (≥18 years of age) with severe SCD (history of recurrent vaso-occlusive crisis [VOC], acute chest syndrome, stroke, or tricuspid regurgitant jet velocity of >2.5 m/s) were screened for eligibility. For group B, at least 2 months of regular transfusions (target Hb 10-12 g/dL and target HbS <30%) were initiated. Following bone marrow harvest (BMH), autologous CD34+ cells were transduced with the BB305 vector. Subjects underwent fully myeloablative conditioning prior to infusion of the transduced cells. After infusion, patients were monitored for adverse events (AEs), engraftment, vector copy number (VCN), HbAT87Q expression, and laboratory and clinical parameters.


As of July 21, 2017, 9 patients with severe SCD (median age 26 [range 18–42] years) have received LentiGlobin DP. All successfully underwent BMH (median 2 harvests, range 1–3). Eighteen grade 3 AEs in 6 patients were attributed to BMH: pain (12 events), anemia (3 events) and VOC (3 events). Table 1 summarizes DP characteristics and lab results. The median cell dose for group A patients was 2.1 x 106 CD34+ cells/kg, median DP VCN was 0.6 copies/diploid genome, and 8%–42% CD34+ cells were transduced. In group B patients, DP VCNs were 1.4/3.3 and 2.9/5.0 (2 DP lots per patient), DP cell doses were 2.2 and 3.2 x 106 CD34+ cells/kg, and 46%–95% of CD34+ cells were transduced. Median time to neutrophil engraftment (ANC ≥ 500) was 22 days (range 17–29) in group A and 28 days in group B. Median post-infusion follow-up as of June 2, 2017 was 18.3 (14.9–23.8) months in group A. Patients in group B had 1.7 and 5.6 months follow-up as of July 21, 2017. The toxicity profile observed from start of conditioning to latest follow-up was consistent with myeloablative conditioning with single-agent busulfan. To date, there have been no DP-related ≥ grade 3 AEs. Sixteen SAEs in 7 patients have been reported post DP-infusion, including 2 episodes of grade 4 bacteremia, 2 episodes of grade 3 pyrexia, and single episodes of grade 3 long QT syndrome, fever, influenza, wrist fracture, osteonecrosis, pain, iron overload, pulmonary mass, vomiting, diarrhea, and drug dependence.

In group A, median VCN in peripheral blood was 0.1 (0.1–0.2) copies/genome and median HbAT87Q level was 0.9 g/dL (0.4–2.4 g/dL) at last measurement. Patients experiencing multiple VOCs prior to study entry (n=6; median 4, range 2–28 VOCs annually) have had numerically fewer VOCs since LentiGlobin DP infusion (median annualized frequency 1, range 0–24, 14%–100% reduction).

In group B, the marked increases in DP VCN have corresponded to higher early VCNs in peripheral blood, with VCNs in patients 1302 and 1303 of 2.6 and 0.5 at month 1 and month 3, respectively. An additional 8 patients have been enrolled in HGB-206 as of July 21, 2017 but have not yet received DP. Initial data, including mobilization results and DP characteristics, for these patients will be presented.


Early results from 2 patients treated under a modified protocol with LentiGlobin DP manufactured under a refined process demonstrate both higher DP VCN and higher peripheral VCN after transplant. Engraftment times in group B are comparable with group A, and no unexpected AEs have occurred to date. Additional study data should demonstrate whether improvements in LentiGlobin gene therapy will provide consistent clinical benefit to patients with severe SCD.

Disclosures: Kanter: NHLBI (sickle cell disease research advisory committee): Membership on an entity's Board of Directors or advisory committees, Research Funding; Bluebird Bio: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; GBT: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; American Society of Hematology (Sickle Cell Disease Guideline Panel): Membership on an entity's Board of Directors or advisory committees; Sancillo: Research Funding; Pfizer: Research Funding; Apopharma: Research Funding; MUSC: Other: The site PI for sponsored research conducted at MUSC who receives funds from: Novartis, bluebird bio, GBT, Sancillo, Apopharma, Pfizer. Walters: bluebird bio: Research Funding; Sangamo Therapeutics: Consultancy; AllCells, Inc: Other: Medical Director; ViaCord Processing Lab: Other: Medical Director. Kwiatkowski: Novartis: Research Funding; Agios: Consultancy, Honoraria, Research Funding; Bluebird Bio: Consultancy, Research Funding; Apopharma: Research Funding; Ionis: Consultancy, Honoraria. von Kalle: bluebird bio: Consultancy; GeneWerk: Equity Ownership. Joseney-Antoine: bluebird bio: Employment, Equity Ownership. Pierciey: bluebird bio: Employment. Shi: bluebird bio: Employment, Equity Ownership. Asmal: bluebird bio: Employment, Equity Ownership. Thompson: Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Baxalta: Research Funding; bluebird bio: Consultancy, Research Funding.

*signifies non-member of ASH